Skip to main content
. 2023 Jun 16;13:1105474. doi: 10.3389/fonc.2023.1105474

Table 4.

The overall response rate and disease control rate of pyrotinib in HER2-positive breast cancers with brain metastasis.

Best response No. (%) (n = 35)
CR 2 (5.7)
PR 14 (40.0)
SD 10 (28.6)
PD 9 (25.7)
ORR 14 (45.7)
DCR 24 (74.3)

Values are presented as number (%).

CR, complete response; DCR, disease control rate; HER2, human epidermal growth factor receptor 2; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.